Bibliographic Details
| Title: |
Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency |
| Authors: |
Antonin Schmitt, Bernard Royer, Romain Boidot, Joseph Berthier, François Ghiringhelli |
| Source: |
Frontiers in Oncology, Vol 13 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
uracilemia, DPD deficiency, 5-Fu (5-Fluorouracil), esophageal cancer, therapeutic drug monitoring, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Esophageal cancer is a cancer with poor prognosis and the standard 1st line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2234-943X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fonc.2023.1187052/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2023.1187052 |
| Access URL: |
https://doaj.org/article/fb43c09a336148f89968870d2201a771 |
| Accession Number: |
edsdoj.fb43c09a336148f89968870d2201a771 |
| Database: |
Directory of Open Access Journals |
